87 related articles for article (PubMed ID: 12756208)
1. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
2. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism.
Oleson L; von Moltke LL; Greenblatt DJ; Court MH
Xenobiotica; 2010 Feb; 40(2):146-62. PubMed ID: 20082578
[TBL] [Abstract][Full Text] [Related]
3. The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin.
Liu JE; Ren B; Tang L; Tang QJ; Liu XY; Li X; Bai X; Zhong WP; Meng JX; Lin HM; Wu H; Chen JY; Zhong SL
Sci Rep; 2016 May; 6():26544. PubMed ID: 27211076
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
Fohner AE; Dalton R; Skagen K; Jackson K; Claw KG; Hopkins SE; Robinson R; Khan BA; Prasad B; Schuetz EG; Nickerson DA; Thornton TA; Dillard DA; Boyer BB; Thummel KE; Woodahl EL
Clin Transl Sci; 2021 Jul; 14(4):1292-1302. PubMed ID: 33503331
[TBL] [Abstract][Full Text] [Related]
5. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
[TBL] [Abstract][Full Text] [Related]
6. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Lolodi O; Wang YM; Wright WC; Chen T
Curr Drug Metab; 2017; 18(12):1095-1105. PubMed ID: 28558634
[TBL] [Abstract][Full Text] [Related]
7. MD investigation on the differences in the dynamic interactions between the specific ligand azamulin and two CYP3A isoforms, 3A4 and 3A5.
Liu S; Jing T; Jia R; Zhang JL; Bai FQ
J Biomol Struct Dyn; 2024 Mar; ():1-10. PubMed ID: 38533567
[TBL] [Abstract][Full Text] [Related]
8. Signatures of Co-evolution and Co-regulation in the CYP3A and CYP4F Genes in Humans.
Richard-St-Hilaire A; Gamache I; Pelletier J; Grenier JC; Poujol R; Hussin JG
Genome Biol Evol; 2024 Jan; 16(1):. PubMed ID: 38207129
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson GR
J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.
Peter JU; Dieudonné P; Zolk O
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675433
[TBL] [Abstract][Full Text] [Related]
11. Genetic Determinants of Response to Statins in Cardiovascular Diseases.
Ghorbannezhad G; Mehrabadi S; Golampour-Shamkani N; Barjasteh A; Etesamizadeh P; Tayyebi M; Khazaei M; Hassanian SM; Ferns GA; Avan A
Curr Cardiol Rev; 2024; 20(2):20-28. PubMed ID: 38204221
[TBL] [Abstract][Full Text] [Related]
12. Differences of Atomic-Level Interactions between Midazolam and Two CYP Isoforms 3A4 and 3A5.
Liu S; Zheng Q; Bai F
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836743
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG; IJzerman NS; van Meekeren M; Oomen-de Hoop E; Guchelaar NAD; Visser AMW; Matic M; van Schaik RHN; de Bruijn P; Moes DAR; Jobse PA; Gelderblom H; Huitema ADR; Steeghs N; Mathijssen RHJ; Koolen SLW;
Clin Pharmacokinet; 2023 Aug; 62(8):1129-1139. PubMed ID: 37310647
[TBL] [Abstract][Full Text] [Related]
14. The Role of CYP3A in Health and Disease.
Klyushova LS; Perepechaeva ML; Grishanova AY
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359206
[TBL] [Abstract][Full Text] [Related]
15. Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma.
Wang Y; Wang C; Zhang Y; Hao J; Yang N; Wang J; Peng M; Liu T; Zhang G; Zhan X; Zeng S; Zhang Y; Gao Y; Yao Y
Front Oncol; 2022; 12():876899. PubMed ID: 36330490
[TBL] [Abstract][Full Text] [Related]
16. Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome
Zhao S; Wesseling S; Rietjens IMCM; Strikwold M
Arch Toxicol; 2022 May; 96(5):1387-1409. PubMed ID: 35294598
[TBL] [Abstract][Full Text] [Related]
17. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs.
Molenaar-Kuijsten L; Van Balen DEM; Beijnen JH; Steeghs N; Huitema ADR
Front Pharmacol; 2021; 12():670862. PubMed ID: 34526892
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in
Yadav J; El Hassani M; Sodhi J; Lauschke VM; Hartman JH; Russell LE
Drug Metab Rev; 2021 May; 53(2):207-233. PubMed ID: 33989099
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment.
Pernaute-Lau L; Adegnika AA; Zhou Y; Zinsou JF; Gil JP; Krishna S; Kremsner PG; Lauschke VM; Velavan TP
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0027521. PubMed ID: 33875422
[TBL] [Abstract][Full Text] [Related]
20. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.
Saiz-Rodríguez M; Almenara S; Navares-Gómez M; Ochoa D; Román M; Zubiaur P; Koller D; Santos M; Mejía G; Borobia AM; Rodríguez-Antona C; Abad-Santos F
Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32331352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
